Phospho-Jak1 (Tyr1022/1023) (F11) rabbit mAb FITC Conjugate
Jak1 plays an essential role in the IFN-α and IFN-γ response pathways and is tyrosine-phosphorylated upon cellular exposure to these signals. Jak1 oral inhibitors have been used to benefit patients with advanced myelofibrosis, where Jak1 was initially shown to be constitutively active in the peripheral blood cells of these patients. Targeted, small-molecule Jak inhibitors have also been used for treatment of rheumatoid arthritis. In cases of advanced melanoma, acquired resistance to PD-1 blockade drugs is associated with loss-of-functions of mutations in Jak1/2 genes. These mutations block interferon gamma signaling and prevent programmed death ligand 1 (PD-L1) expression in tumor cells.
|Cross Reactivity||Predicted to work with mouse, rat and other homologues.|
|Immunogen||A synthetic phospho-peptide corresponding to residues surrounding Tyr1022/1023 of human phospho-Jak1|
|Formulation||1X PBS, 0.09% NaN3, 0.2% BSA|
|Recommended Usage||For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells or 5 µL per 100 µL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.|
|Pseudonyms||Tyrosine-protein kinase JAK1, Janus kinase 1|
|References||Muller M, et al. (1993) Nature. 366: 129-135.
Verstovesk S, et al. New England Journal of Medicine. 363: 1117-1127.
Shin DS, et al. (2017) Cancer Discovery. 7:188-201.
Boyle DL, et al. (2014) Annals of the Rheumatic Diseases. 74: 1311-1316.
Phospho-Lck (Tyr505) (A3) rabbit mAb SureLight®488 conjugateCatalog #: 2305
Phospho-Chk1 (Ser317) (G1) rabbit mAb PE conjugateCatalog #: 2262